Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 3/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13339221 | 0.96 | SIRT2 (0.35) | SIRT2SIRT1ACETGM2SIRT3 | |
| SCHEMBL13167106 | 0.95 | ACE (0.36) | SIRT2SIRT1ACETGM2SIRT3 | |
| SCHEMBL12692567 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1TGM2SIRT3HDAC4 | |
| SCHEMBL12424727 | 0.92 | ACE (0.36) | SIRT2SIRT1ACETGM2KLK7 | |
| SCHEMBL2756775 | 0.88 | SIRT2 (0.36) | SIRT2SIRT1TGM2SIRT3KLK7 | |
| SCHEMBL327848 | 0.88 | EPHX1 (0.38) | SIRT2SIRT1TGM2SIRT3KLK7 | |
| SCHEMBL10017795 | 0.88 | EPHX1 (0.38) | SIRT2SIRT1TGM2SIRT3KLK7 | |
| SCHEMBL12421777 | 0.86 | SIRT2 (0.32) | SIRT2SIRT1ACETGM2SIRT3 | |
| SCHEMBL12990568 | 0.85 | HPGD (0.35) | SIRT2SIRT1TGM2SIRT3KLK7 | |
| SCHEMBL12509746 | 0.84 | SIRT1 (0.38) | SIRT2SIRT1TGM2SIRT3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763995-B2 | Polymer conjugates of protegrin peptides | NEKTAR THERAPEUTICS (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9539337-B2 | Compositions comprising two different populations of polymer-active agent conjugates | NEKTAR THERAPEUTICS (US) | 2017-01-10 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-9421275-B2 | Oligomer-calcimimetic conjugates and related compunds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2016-06-23 | — | — | US | disclosed |
| US-20100010158-A1 | Segmented Degradable Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS | 2010-01-14 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080319091-A1 | Polymer Derivatives Comprising an Imide Branching Point | NEKTAR THERAPEUTICS AL, CORPORATION | 2008-12-25 | — | — | US | disclosed |
| US-20080299069-A1 | Polymer Derivatives Comprising an Acetal or Ketal Branching Point | NEKTAR THERAPEUTICS | 2008-12-04 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070031371-A1 | Method for Preparing Branched Functionalized Polymers Using Branched Polyol Cores | NEKTAR THERAPEUTICS AL, CORPORATION | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | SIRT2 4529/4885SIRT1 4665/4885ACE 3983/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT2 4162/4885SIRT1 3966/4885ACE 3042/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | SIRT2 4032/4885SIRT1 3515/4885ACE 2911/4885 |
| US-20080299069-A1 | Polymer Derivatives Comprising an Acetal or Ketal Branching Point | ILK, KARS1, AKR1C2 | SIRT2 410/4885SIRT1 284/4885ACE 2404/4885 |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT2 4157/4885SIRT1 4382/4885ACE 2726/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | SIRT2 4032/4885SIRT1 3894/4885ACE 3799/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | SIRT2 4490/4885SIRT1 4397/4885ACE 2877/4885 |
| US-20070031371-A1 | Method for Preparing Branched Functionalized Polymers Using Branched Polyol Cores | PARG, VIP, PHYKPL | SIRT2 3354/4885SIRT1 3618/4885ACE 2245/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | SIRT2 2813/4885SIRT1 2294/4885ACE 2973/4885 |
| US-20080319091-A1 | Polymer Derivatives Comprising an Imide Branching Point | INCENP, ILK, PIM3 | SIRT2 1187/4885SIRT1 812/4885ACE 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.